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The anticancer and immunosuppressant thiopurines cause 6-thioguanine (6-TG) to accumulate in
nuclear DNA. We report that 6-TG is also readily incorporated into mitochondrial DNA (mtDNA)
where it is rapidly oxidized. The oxidized forms of mtDNA 6-TG inhibit replication by DNA Pol-c.
Accumulation of oxidized 6-TG is associated with reduced mtDNA transcription, a decline in mito-
chondrial protein levels, and loss of mitochondrial function. Ultraviolet A radiation (UVA) also oxi-
dizes mtDNA 6-TG. Cells without mtDNA are less sensitive to killing by a combination of 6-TG and
UVA than their mtDNA-containing counterparts, indicating that photochemical mtDNA 6-TG oxida-
tion contributes to 6-TG-mediated UVA photosensitization.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The thiopurines azathioprine, 6-thioguanine (6-TG) and 6-mer-
captopurine (6-MP) are prescribed extensively as immunosuppres-
sants, anticancer or antiinﬂammatory agents. Systemic thiopurine
treatment causes the accumulation of DNA 6-TG which interacts
with DNA mismatch repair to cause cell death. Selective toxicity
to activated immune effector cells underlies their therapeutic ef-
fect (reviewed in [1]).
DNA 6-TG readily undergoes chemical modiﬁcation [2]. In par-
ticular, 6-TG has a lower oxidation potential than the canonical
DNA bases and is highly vulnerable to oxidation by reactive oxygen
species (ROS). Oxidation of DNA 6-TG is cytotoxic and cells con-
taining DNA 6-TG are hypersensitive to oxidants such as H2O2,
KBrO3 and the ROS generated by immune effector cells [3]. The ma-
jor forms of oxidized DNA 6-TG, DNA guanine-6-sulfonate (GSO3)
[4] and guanine-6-sulﬁnate (GSO2) [5] are extremely effective
DNA replication and transcription blocks [6,7] and are refractory
to excision repair [7,8]. These lesions are also generated photo-chemical Societies. Published by E
), peter.karran@cancer.org.uk
logy, Mount Sinai School of
earch, Wilmslow Road, Man-chemically when DNA 6-TG acts as a UVA photosensitizer to gen-
erate ROS [4].
To date, the focus has been on the oxidative reactions of nuclear
DNA 6-TG (nDNA). Mitochondrial DNA (mtDNA) is, however, par-
ticularly vulnerable to endogenous oxidation. Mitochondria con-
tain multiple copies of a 16.5 kb circular DNA encoding 13
polypeptides which are essential for oxidative phosphorylation
(reviewed in [9,10]). Electron leakage during oxidative phosphory-
lation is the major source of cellular ROS [11] to which mtDNA is
particularly vulnerable [12] owing to its proximity to the electron
transport chain and the absence of protective histones. Extensive
mtDNA damage leads to mitochondrial dysfunction – loss of elec-
tron transport, mitochondrial membrane potential, and ATP gener-
ation – and eventually to cell death [13]. mtDNA is protected by
antioxidants and mitochondrial DNA repair systems including,
but not limited to, the base excision repair of mtDNA bases such
as 8-oxoGuanine [14,15].
A delicate balance between the formation and excision of oxi-
dized mtDNA bases is required to maintain mitochondrial function
and conditions of oxidative stress can be particularly dangerous to
mtDNA integrity and mitochondrial function. The presence of a
vulnerable oxidation target in mtDNA might also upset this bal-
ance. Here we report that 6-TG is incorporated into mtDNA where
it is rapidly oxidized. The accumulation of these oxidation products
is associated with mitochondrial dysfunction and 6-TG
cytotoxicity.lsevier B.V. All rights reserved.
Fig. 1. 6-TG incorporation by nDNA and mtDNA. HCT116 (A) and J774a.1 (B) cells
were grown in the presence of 1 lM 6-TG. Nuclei and mitochondria were separated
and nDNA (j) or mtDNA (s) was extracted, digested to deoxynucleosides and
analyzed by HPLC. 6-TG incorporation is normalized to the amount of dG in the
same DNA sample. Data are from four (HCT116) or three (J774a-1) experiments,
respectively.
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Unless stated, all chemicals were from Sigma–Aldrich.
2.1. Cell culture
Human SV40-transformed MRC5-VA ﬁbroblasts, HCT116 colon
carcinoma, and J774a.1 murine macrophage precursor cells were
maintained in Dulbecco’s MEM supplemented with 10% FCS
(Gibco/Invitrogen).
2.2. DNA isolation
DNA was extracted from separated nuclei and mitochondria
using the Wizard Genomic DNA puriﬁcation kit (Promega) and
the Promokine Mitochondrial DNA Isolation kit (PromoCell),
respectively.
2.3. Quantitation of DNA 6-TG
DNA was digested and analyzed as described [4]. 6-TG substitu-
tion is expressed relative to deoxyguanosine in the same sample.
2.4. Detection of ROS
Cells were incubated with the ﬂuorescent dye CMH2DCFDA
(Molecular Probes) for 20 min at 37 C, detached by trypsinization
and ﬂuorescence was analyzed by FACS.
2.5. Cell survival
Five hundred cells/well were seeded in triplicates into 6-well
plates in medium in the absence or presence of pyruvate
(100 lg/ml) and uridine (50 lg/ml). After 7–10 days, Giemsa-
stained colonies were counted. Each experiment was performed
at least three times.
2.6. mtDNA synthesis
2  106 Cells were preincubated with aphidicolin (15 lM, 1 h)
and labeled with [50 3H]-thymidine (2 lCi/ml) for 6 h at 37 C.
TCA-insoluble radioactivity was determined by scintillation count-
ing. Experiments were performed in triplicate.
2.7. Primer extension
Primer extensions were carried out as described [6]. Brieﬂy, 26-
mer templates containing either a G or a 6-TG were annealed to
[32P] end-labeled 11-mer primers, supplemented with deoxyribo-
nucleoside triphosphates (4 lM) and extended for 1 min at 37 C
by Pol-c. Products were analyzed on 16% polyacrylamide gels.
Template 6-TG was oxidized by 10 kJ/m2 UVA, MMPP (1 mM,
20 min), H2O2 (100 mM, 5 min) or Rose Bengal (RB) and visible
light (20 lM, 60 W bulb/2 h) [5]. Oligonucleotide sequences were:
Template strand 50-CGATCTGATGTXCGAGCAGACAGCAG-30
(X@G or 6-TG); Primer 50-CTGCTGTCTGC-30.
2.8. Immunoblotting
30 lg Protein was separated on 4–20% Tris–Glycine (Invitrogen)
gels. After transfer, membranes were probed with antibodies
against complex IV subunit I (Cox1; Molecular Probes, 1:1000),
complex V subunit a (ATP5A1; Molecular Probes, 1:1000), and
complex IV subunit IV (Cox4; Molecular Probes, 1:1000). Protein
detection was by the ECL detection reagent (GE Healthcare).2.9. QPCR
2 lg (in 50 ll) Trizol (Invitrogen)-extracted total RNA was re-
verse-transcribed using the Illustra Ready-To-Go RT–PCR beads
(GE Healthcare). Real-time PCR (BioRad CFX96 cycler) consisted
of 10 min initial denaturation at 95 C, followed by 40 cycles of
15 s at 95 C and 60 s at 58 C. Reactions were prepared with SYBR
Green (Fermentas), using 1 ll cDNA and 10 pmoles of each primer
in 25 ll total volume. GAPDH was used as a reference. Expression
ratios were calculated with the DD ct method. Primers were:
GAPDH F: 50 GAAGGTGAAGGTCGGAGTC 30
GAPDH R: 50 GAAGATGGTGATGGGATTTC 30
NDUFA4 F: 50 CAGAGCCCTGGAACAAACTGGG 30
NDUFA4 R: 50 GACCTTCATTCTAAAGCAGCG 30
Nd6 F: 50 GGATCCTCCCGAATCAAC 30
Nd6 R: 50 GTAGGATTGGTGCTGTGG 30
Cox1 F: 50 AACGTTGTAGGCCCCTACGGG 30
Cox1 R: 50 GTGAGAGCTAAGGTCGGGGCG 30
2.10. ATP
ATP was measured by the ATP Determination Kit (Molecular
Probes, Eugene, OR). 560 nm luminescence was measured on a
PHERAstar Microplate Reader. Protein concentrations were deter-
mined by Bradford assay.
3. Results
3.1. Nuclear and mitochondrial DNA substitution by chronic 6-TG
treatment
We examined 6-TG accumulation in nuclear and mtDNA of hu-
man HCT116 colorectal carcinoma and J774a.1 murine macro-
phage precursor cells grown in medium containing 1 lM 6-TG.
Deoxynucleoside digests of nuclear and mtDNA were separated
by HPLC and deoxyguanosine and 6-thiodeoxyguanosine were
quantiﬁed by A260 and A342, respectively. After 48 h, 6-TG replaced
0.3% of guanine in both nDNA and mtDNA in HCT116 cells (Fig. 1A).
6-TG incorporation by J774.a cells was around two-fold higher
(Fig. 1B). These DNA 6-TG levels did not change signiﬁcantly fol-
lowing continued growth for further 8 days in the presence of
the thiopurine.
3.2. Oxidation of DNA 6-TG
mtDNA 6-TG undergoes rapid oxidation. Fig. 2A and B show that
during 10 days of continuous 6-TG treatment, the oxidized form of
Fig. 2. Oxidation of nDNA 6-TG versus mtDNA 6-TG and endogenous ROS. DNA
from HCT116 (A) and J774a.1 (B) was extracted from nuclei (s) or mitochondria
(d), digested to nucleosides and separated by HPLC. Values are expressed as a ratio
of oxidized (GSO3) to unoxidized DNA 6-TG. (C) Endogenous ROS levels in HCT116
(black) and J774a.1 (gray) were determined by CMH2DCFDA staining and FACS.
Data are from four (HCT116) or three (J774a-1) experiments, respectively.
Fig. 3. mtDNA replication and 6-TG oxidation. (A) In vivo. HCT116 cells treated
with 1 lM 6-TG for 24 h were incubated with 15 lM aphidicolin for 1 h followed by
1 h with 0.5 mM H2O2 or 100 lM EtBr as indicated. Control cells (-) received only
aphidicolin. All cells were then labeled with [3H]-thymidine (2 lCi/ml) for 6 h and
TCA-insoluble radioactivity in mtDNA was determined. Data are expressed as
percentage incorporation compared to that of cells receiving aphidicolin alone. A
representative of two independent experiments is shown. (B) 6-thio-dGTP utiliza-
tion by DNA Pol-c. An 11-mer radiolabeled primer annealed to a 26-mer
oligodeoxynucleotide template was extended for 60 s by Pol-c in the presence of
dTTP, dATP, dCTP and 6-thio-dGTP (all 4 lM). (C) Inhibition of Pol-c by a template
oxidized DNA 6-TG. 26-mer templates containing either a G or a single 6-TG at the
position indicated were treated with: MMPP, Rose Bengal (RB) ± visible light (VL),
H2O2 or UVA. Treated templates were annealed to an 11-mer primer that was
extended by Pol-c for 60 s in the presence of the four normal deoxyribonucleoside
triphosphates. Products were separated by PAGE and visualized by autoradiogra-
phy. The gel shown is representative of three independent experiments. The
positions of the single template 6-TG and the corresponding G in the control
template are shown arrowed and boxed.
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nDNA 6-TG oxidation was signiﬁcantly slower. mtDNA GSO3 accu-
mulation was correlated with ROS production and the higher stea-
dy-state levels of ROS in J774a.1 cells were associated with
increased mDNA 6-TG oxidation (Fig. 2C). The role of endogenous
ROS in mtDNA 6-TG oxidation was conﬁrmed by depleting the le-
vel of antioxidant protection. The glutathione synthetase inhibitor
BSO measurably increased both the steady-state ROS levels and the
rate of mtDNA 6-TG oxidation in HCT116 cells (Supplementary
Fig. S1).
3.3. Oxidized mtDNA 6-TG and mtDNA replication
Oxidized DNA 6-TG lesions block nuclear DNA replication and
arrest primer extension in vitro. We examined whether they af-
fected mtDNA replication. HCT116 cells were treated with 6-TG
and aphidicolin to suppress nDNA replication by over 99% as deter-
mined by [3H]-thymidine incorporation. The treated cells were
then exposed to H2O2 for 1 h to oxidize mtDNA 6-TG and allowed
to incorporate [3H]-thymidine for a further 6 h. mtDNA and nDNA
radioactivity was quantiﬁed. Combined H2O2 and 6-TG treatment
reduced [3H]-thymidine incorporation into mtDNA by >90%
(Fig. 3A). Inhibition was comparable to that induced by overnight
treatment of cells with ethidium bromide, a known inhibitor of
mtDNA replication. These ﬁndings suggest that oxidized 6-TG le-
sions inhibit mtDNA replication.
Primer extension experiments were used to examine the utili-
zation of 6-thio-dGTP by mitochondrial DNA polymerase c (Pol-
c) and the effects of oxidized DNA 6-TG on Pol-c activity. 6-thio-
dGTP was a good substrate for Pol-c. Primer extension on a
26mer template comprising canonical nucleobases utilizing a dNTP
mix in which 6-thio-dGTP replaced dGTP was efﬁcient and puriﬁed
Pol-c produced a full-length product (Fig. 3B).
An oxidized template 6-TG was an effective inhibitor of Pol-c.
6-TG-containing templates exposed to mild oxidizing treatments
were used as substrates for elongation. Oxidation caused a signiﬁ-
cant inhibition of Pol-c and extension was arrested at the baseimmediately preceding or opposite the oxidized 6-TG (Fig. 3C).
Non-oxidized 6-TG impeded primer elongation only slightly.
MMPP treatment which stoichiometrically converted 6-TG to
GSO3, the bulkiest of the 6-TG oxidation products, caused the most
pronounced inhibition. Inhibition was less marked after exposure
to UVA, H2O2 or Rose Bengal plus visible light (VL) each of which
induced only partial 6-TG oxidation. None of the treatments detec-
tably affected primer extension on the G template and complete
extension occurred on both untreated and oxidized templates.
3.4. Oxidized mtDNA 6-TG mitochondrial protein expression
We examined the effect of chronic 6-TG treatment on mtDNA
transcription. DNA GSO3 inhibits nuclear transcription [7]. Because
6-TG incorporation into RNA is low [7], it is unlikely to affect re-
verse transcription. RNA from HCT116 cells grown with 6-TG was
therefore analyzed by quantitative RT–PCR. After 10 days of
Fig. 4. Reduced mt gene transcription and protein expression in 6-TG-treated cells.
(A) Transcripts. HCT116 cells were treated with 1 lM 6-TG for 0, 4 or 10 days.
Levels of mRNAs for Cytochrome c oxidase Complex IV Subunit I (COX1), NADH-
ubiquinol oxidoreductase 6 (ND6), and NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex 4 (NDUFA4) were determined by qRT–PCR. (B) Mitochondrial protein.
HCT116 cells were treated with 1 lM 6-TG. At the times indicated, proteins were
analyzed by Western blotting.
Fig. 5. ATP levels in 6-TG treated cells. (A) HCT116 cells were cultured in the
presence of 1 lM 6-TG. ATP levels were measured at the times shown. At 24 h, 6-TG
was removed and ATP level was measured 24 h later (48). (B) HCT116 cells were
maintained in the presence of 1 lM 6-TG and ATP levels were measured at daily
intervals. At 10 days, 6-TG was removed and ATP level was measured 2 days later
(10 + 2).
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nd6 transcripts were reduced by approximately 70% compared to
untreated cells. In contrast, transcription of the nuclear-encoded
mitochondrial Ndufa4 protein was reduced by 640% (Fig. 4A).
Progressive accumulation of transcription-blocking lesions in
mtDNA was associated with reduced production of mitochondrial-
ly-encoded proteins. HCT116 cells expressed detectably less Cox1
protein after 8 days of 6-TG treatment (Fig. 4B). In contrast, the
nDNA-encoded Cox4 protein was present at unchanged levels
throughout the 10-day treatment.
Analysis of the nDNA-encoded mitochondrial Atp5a1 and Nduf3
proteins conﬁrmed the effect on mitochondrial protein expression.
Both these proteins are stabilized by a mtDNA-encoded partner
and in its absence the orphan protein is degraded. Atp5a1 and
Nduf3 levels were detectably reduced by day eight of 6-TG treat-
ment (Fig. 4B) consistent with reduced expression of essential
mtDNA-encoded proteins.
3.5. ATP production
Consistent with previous reports [16], 6-TG treatment caused a
rapid and reversible depletion of cellular ATP. After 24 h exposure
to 6-TG, ATP concentrations recovered to pre-treatment levels fol-
lowing return to normal growth medium (Fig. 5A). In the continued
presence of 6-TG, low ATP concentrations were maintained for up
to 10 days (Fig. 5B). This chronic depression of ATP levels was asso-
ciated with an irreversible inhibition of ATP production. Beyond
4 days, ATP levels did not recover following return to normal med-
ium. ATP levels also declined irreversibly in J774a.1 (data not
shown). Thus, a progressive accumulation of mtDNA damage and
impaired synthesis of essential mitochondrial proteins is associ-
ated with reduced ATP levels.3.6. mtDNA 6-TG and UVA sensitivity
mtDNA 6-TG was also a target for photochemical oxidation.
UVA induced a dose-dependent increase in mtDNA GSO3
(Fig. 6A). Photochemical mtDNA 6-TG oxidation affected cell viabil-
ity. q0 HCT116 cells, isolated by continuous treatment with ethi-
dium bromide in uridine- and pyruvate-supplemented medium
[17], were unable to grow in the absence of supplements, conﬁrm-
ing their q0 status (Fig. 6B). Fig. 6C shows that 6-TG-treated q0
HCT116 cells were more resistant to UVA than their q+ counter-
parts. This suggests that the photochemical oxidation of mtDNA
6-TG compromises cell survival.
4. Discussion
DNA 6-TG is unambiguously implicated in the cytotoxicity of
thiopurines (reviewed in [1]). Following acute treatment with high
6-TG concentrations, nDNA 6-TG interacts with DNA mismatch re-
pair to cause cell death. In the experiments described here we
examined the effects of extended treatment with 6-TG concentra-
tions that permitted continuing cell proliferation – conditions
more akin to those in renewing cell populations of thiopurine-
treated patients – and found that 6-TG accumulates to similar
extents in nuclear and mtDNA. mtDNA is particularly vulnerable
to oxidative damage. The presence of oxidation-prone DNA 6-TG
exacerbates the inevitable threat from aerobic metabolism.
Oxidized 6-TG was a strong block to mtDNA replication and to
DNA Pol-c. These lesions inhibit nDNA transcription [7] and their
accumulation in mtDNA was accompanied by reduced levels of
Fig. 6. UVA sensitivity of 6-TG treated q+ and q0 HCT116 cells. (A) UVA induced
oxidation of mtDNA 6-TG. 6-TG treated (1 lM, 24 h) cells were irradiated with UVA
as shown. mtDNA was extracted and GSO3 was quantiﬁed. Values are expressed as
a ratio of oxidized to unoxidized mtDNA 6-TG. (B) q0 HCT116 cells. HCT116 cells
were grown in medium supplemented with uridine and pyruvate and containing
20 lM EtBr. At the times indicated, aliquots of cells were transferred to unsupple-
mented growth medium and cell viability was determined by clonal assay. The data
represent the mean ± SD of three separate experiments. (C) Survival. HCT116 q+(d),
HCT116 q0 (s) cells were grown in the presence of 1 lM 6-TG for 48 h. mtDNA
substitution was 0.25% of DNA G. Cells were exposed to UVA at the doses indicated
and cell survival was determined by clonal assay. The data points represent the
mean ± SD of three independent experiments.
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products. This suggests that chronic thiopurine treatment may
cause a deterioration in mitochondrial function as a consequence
of both reduced mtDNA content and inhibited expression of
mtDNA-encoded proteins. The accompanying irreversible impair-
ment of ATP production is consistent with this possibility.
DNA 6-TG is also a UVA photosensitizer and the interaction be-
tween nDNA 6-TG and UVA induces ROS that cause multiple forms
of cytotoxic DNA damage. Our ﬁndings indicate that mtDNA is sim-
ilarly vulnerable to photooxidation and the decreased sensitivity of
q0 cells to combined 6-TG/UVA indicate that the formation of oxi-
dized mtDNA 6-TG contributes to the synergistic cytotoxicity of 6-
TG and UVA.
Toxic effects due to mtDNA damage or interference with
mtDNA replication have clinical counterparts. The DNA intercalat-
ing anthracyclines such as doxorubicin, cause chronic cardiomyop-
athy related to loss of mtDNA and its encoded proteins [18]. In
addition, long-term use of antiretroviral nucleoside reverse trans-
criptase inhibitors, such as zidovudine, is frequently associated
with severe mitochondrial dysfunction and myopathy [19]. This
reversible side effect probably reﬂects inhibition of Pol-c or inter-
ference with mtDNA replication [20]. Reversible myopathy and
muscular weakness can accompany azathioprine treatment [21]
which also causes DNA 6-TG accumulation [22]. Non-fatal liver
toxicity is an acknowledged thiopurine side-effect. A meta analysis
of liver function in IBD patients taking 6-MP or azathioprine [23]
revealed frequent mild, transient and self-limiting hepatotoxicity.
More serious toxicity necessitating drug withdrawal affected
around 4% of patients. Among children undergoing thiopurine
therapy for lymphoblastic leukemia, 11% of the 6-TG group
developed symptoms of hepatotoxicity. Nodular regenerativehyperplasia of the liver is often observed in IBD patients treated
with 6-TG [24,25] and can affect up to 60% of patients [26].
These clinical reports demonstrate thiopurine cytotoxicity in
non-dividing tissues such as muscle and liver. The previously
unrecognized properties of mtDNA 6-TG that we describe here
may go some way to explaining the observed hepatotoxicity and
myopathy that are side effects of thiopurine treatment.
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